Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Sutro Biopharma, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 113 | 3 | 119 | +9 |
| Shares | 50.4M | 187.2K | 50.0M | −225.9K (−0.5%) |
| Value | $279.6M | $1.04M | $403.7M | +$125.1M (+44.9%) |
3 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Sutro Biopharma, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Kynam Capital Management, LP | 404,544 | $3.27M | 0.50% |
| Norges Bank | 206,200 | $1.67M | 0.00% |
| Caas Capital Management LP | 115,981 | $937.1K | 0.18% |
| Rafferty Asset Management, LLC | 98,637 | $797.0K | 0.01% |
| Susquehanna Fundamental Investments, LLC | 77,064 | $622.7K | 0.01% |
| Pura Vida Investments, LLC | 31,409 | $253.8K | 0.04% |
| Bailard, Inc. | 20,300 | $164.0K | 0.01% |
| Prelude Capital Management, LLC | 19,257 | $155.6K | 0.01% |
| Balyasny Asset Management LLC | 17,610 | $142.3K | 0.00% |
| Jane Street Group, LLC | 17,553 | $141.8K | 0.00% |
| Two Sigma Securities, LLC | 15,567 | $125.8K | 0.02% |
| American Century Companies Inc | 12,823 | $103.6K | 0.00% |
| ProShare Advisors LLC | 11,690 | $94.5K | 0.00% |
| Vontobel Holding Ltd. | 10,000 | $80.8K | 0.00% |
| Advisor Group Holdings, Inc. | 9,500 | $76.8K | 0.00% |
| Nisa Investment Advisors, LLC | 80 | $1.00K | 0.00% |
| Allworth Financial LP | 41 | $331 | 0.00% |
| CWM, LLC | 33 | $0 | 0.00% |
Sold out (9)
Institutions that held Sutro Biopharma, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Eventide Asset Management, LLC | 2,708,975 | $15.0M |
| Healthcare of Ontario Pension Plan Trust Fund | 150,000 | $833.0K |
| DAFNA Capital Management LLC | 81,200 | $451.0K |
| PDT Partners, LLC | 74,663 | $414.0K |
| Woodline Partners LP | 73,954 | $410.0K |
| Occudo Quantitative Strategies LP | 44,550 | $247.0K |
| Victory Capital Management Inc | 35,119 | $195.0K |
| Susquehanna International Group, LLP | 15,575 | $86.0K |
| Simplex Trading, LLC | 487 | $2.00K |
Not filed for Q4 2022 yet (3)
Institutions that held Sutro Biopharma, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| AJU IB Investment Co., Ltd. | 175,000 | $971.0K |
| American Portfolios Advisors | 10,000 | $55.5K |
| FourThought Financial, LLC | 2,156 | $12.0K |